Back to Search Start Over

Rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke: the Japan Statin Treatment Against Recurrent Stroke (J-STARS).

Authors :
Nagai Y
Kohriyama T
Origasa H
Minematsu K
Yokota C
Uchiyama S
Ibayashi S
Terayama Y
Takagi M
Kitagawa K
Nomura E
Hosomi N
Ohtsuki T
Yamawaki T
Matsubara Y
Nakamura M
Yamasaki Y
Mori E
Fukushima M
Kobayashi S
Shinohara Y
Yamaguchi T
Matsumoto M
Source :
International journal of stroke : official journal of the International Stroke Society [Int J Stroke] 2014 Feb; Vol. 9 (2), pp. 232-9. Date of Electronic Publication: 2013 Sep 09.
Publication Year :
2014

Abstract

Background: Although statin therapy is beneficial for preventing first strokes, the benefit for recurrent stroke and its sub-types remains unknown in Asian populations. The aim of this study is to examine the role of pravastatin in the secondary prevention of stroke in Japanese patients.<br />Methods: This is a multicenter, randomized, open-label, parallel group study of patients with noncardioembolic ischemic stroke (atherothrombotic infarction, lacunar infarction, and infarction of undetermined etiology). All patients were diagnosed with hyperlipidemia and with a total cholesterol level between 180 and 240 mg/dl at enrollment. Patients in the treatment group receive 10 mg/day of pravastatin, and those in the control group receive no statin treatment. The primary end-point is the recurrence of stroke, including transient ischemic attack. The secondary end-points include the onset of respective stroke sub-types and functional outcomes related to stroke. The patients were enrolled for five-years and will be followed up for five-years.<br />Results: A total of 1578 eligible patients (age: 66·2 years, men: 68·8%), including 64·2% with lacunar infarction, 25·4% with atherothrombotic infarction, and 10·4% with infarction of undetermined etiology were included in this study. Lipid levels were generally well controlled (total cholesterol: 210·0 mg/dl, low density lipoprotein cholesterol: 129·5 mg/dl) at baseline. In addition, the disability of patients was relatively mild, and cognitive function was preserved in the majority of patients.<br />Conclusion: This article reports the rationale, design, and baseline features of a randomized controlled trial to assess the effects of statin for the secondary prevention of stroke. Follow-ups of patients are in progress and will end in 2014.<br /> (© 2013 The Authors. International Journal of Stroke published by World Stroke Organization.)

Details

Language :
English
ISSN :
1747-4949
Volume :
9
Issue :
2
Database :
MEDLINE
Journal :
International journal of stroke : official journal of the International Stroke Society
Publication Type :
Academic Journal
Accession number :
24015915
Full Text :
https://doi.org/10.1111/ijs.12099